Literature DB >> 31543506

An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19.

Vincent S Shaw1, Mohammadjavad Mohammadi1, Josiah A Quinn1, Harish Vashisth2, Richard R Neubig3.   

Abstract

Regulators of G-protein signaling (RGS) proteins modulate receptor signaling by binding to activated G-protein α-subunits, accelerating GTP hydrolysis. Selective inhibition of RGS proteins increases G-protein activity and may provide unique tissue specificity. Thiadiazolidinones (TDZDs) are covalent inhibitors that act on cysteine residues to inhibit RGS4, RGS8, and RGS19. There is a correlation between protein flexibility and potency of inhibition by the TDZD 4-[(4- fluorophenyl)methyl]-2-(4-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione (CCG-50014). In the context of a single conserved cysteine residue on the α 4 helix, RGS19 is the most flexible and most potently inhibited by CCG-50014, followed by RGS4 and RGS8. In this work, we identify residues responsible for differences in both flexibility and potency of inhibition among RGS isoforms. RGS19 lacks a charged residue on the α 4 helix that is present in RGS4 and RGS8. Introducing a negative charge at this position (L118D) increased the thermal stability of RGS19 and decreased the potency of inhibition of CCG-50014 by 8-fold. Mutations eliminating salt bridge formation in RGS8 and RGS4 decreased thermal stability in RGS8 and increased potency of inhibition of both RGS4 and RGS8 by 4- and 2-fold, respectively. Molecular dynamics simulations with an added salt bridge in RGS19 (L118D) showed reduced RGS19 flexibility. Hydrogen-deuterium exchange studies showed striking differences in flexibility in the α 4 helix of RGS4, 8, and 19 with salt bridge-modifying mutations. These results show that the α 4 salt bridge-forming residue controls flexibility in several RGS isoforms and supports a causal relationship between RGS flexibility and the potency of TDZD inhibitors. SIGNIFICANCE STATEMENT: Inhibitor potency is often viewed in relation to the static structure of a target protein binding pocket. Using both experimental and computation studies we assess determinants of dynamics and inhibitor potency for three different RGS proteins. A single salt bridge-forming residue determines differences in flexibility between RGS isoforms; mutations either increase or decrease protein motion with correlated alterations in inhibitor potency. This strongly suggests a causal relationship between RGS protein flexibility and covalent inhibitor potency.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2019        PMID: 31543506      PMCID: PMC6820219          DOI: 10.1124/mol.119.117176

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  31 in total

1.  Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations.

Authors:  Alexander D Mackerell; Michael Feig; Charles L Brooks
Journal:  J Comput Chem       Date:  2004-08       Impact factor: 3.376

2.  RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits.

Authors:  Talia N Lerner; Anatol C Kreitzer
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

3.  Scalable molecular dynamics with NAMD.

Authors:  James C Phillips; Rosemary Braun; Wei Wang; James Gumbart; Emad Tajkhorshid; Elizabeth Villa; Christophe Chipot; Robert D Skeel; Laxmikant Kalé; Klaus Schulten
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

Review 4.  Covalent modifiers: an orthogonal approach to drug design.

Authors:  Michele H Potashman; Mark E Duggan
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

5.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

6.  Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Proteins.

Authors:  Emma M Turner; Levi L Blazer; Richard R Neubig; Stephen M Husbands
Journal:  ACS Med Chem Lett       Date:  2012-02-09       Impact factor: 4.345

7.  Expression of G-protein alpha subunits in Escherichia coli.

Authors:  E Lee; M E Linder; A G Gilman
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

8.  5-HT1A receptor-mediated phosphorylation of extracellular signal-regulated kinases (ERK1/2) is modulated by regulator of G protein signaling protein 19.

Authors:  Qin Wang; Akiko Terauchi; Christopher H Yee; Hisashi Umemori; John R Traynor
Journal:  Cell Signal       Date:  2014-05-02       Impact factor: 4.315

9.  A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins.

Authors:  Levi L Blazer; Haoming Zhang; Emma M Casey; Stephen M Husbands; Richard R Neubig
Journal:  Biochemistry       Date:  2011-03-29       Impact factor: 3.162

Review 10.  Exploring the role of receptor flexibility in structure-based drug discovery.

Authors:  Ferran Feixas; Steffen Lindert; William Sinko; J Andrew McCammon
Journal:  Biophys Chem       Date:  2013-11-09       Impact factor: 2.352

View more
  3 in total

1.  Mixed-solvent molecular dynamics simulation-based discovery of a putative allosteric site on regulator of G protein signaling 4.

Authors:  Wallace K B Chan; Debarati DasGupta; Heather A Carlson; John R Traynor
Journal:  J Comput Chem       Date:  2021-09-07       Impact factor: 3.672

2.  Conserved amino acids in the region connecting membrane spanning domain 1 to nucleotide binding domain 1 are essential for expression of the MRP1 (ABCC1) transporter.

Authors:  Emma E Smith; Gwenaëlle Conseil; Susan P C Cole
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

3.  Allosteric Pathways Originating at Cysteine Residues in Regulators of G-Protein Signaling Proteins.

Authors:  Yong Liu; Harish Vashisth
Journal:  Biophys J       Date:  2020-12-19       Impact factor: 4.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.